Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Xeruborbactam - Qpex Biopharma

Next Previous
Drug Profile

Xeruborbactam - Qpex Biopharma

Alternative Names: BRII-636; OMNIvance®; QPX 7728; ultra broad spectrum intavenous beta-lactamase inhibitors - Qpex Biopharma; ultra broad spectrum oral beta-lactamase inhibitors - Qpex Biopharma

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qpex Biopharma
  • Class Anti-infectives; Antibacterials
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bacterial infections
  • No development reported Acinetobacter infections; Pseudomonal infections

Most Recent Events

  • 28 Jan 2025 Qpex Biopharma completes a phase-I clinical trials in Bacterial infections (In volunteers) (IV) before April 2024
  • 16 Oct 2024 Antimicrobial data from a preclinical studies in Bacterial infections presented at IDWeek 2024
  • 04 Sep 2024 Qpex Biopharma initiates a phase I drug-drug interaction and PK trial for Bacterial infections (In volunteers) in USA (NCT06547554)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top